Spots Global Cancer Trial Database for arsenic trioxide
Every month we try and update this database with for arsenic trioxide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia | NCT00006090 | Leukemia | arsenic trioxid... | 12 Years - | M.D. Anderson Cancer Center | |
| Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma | NCT00185861 | Brain Cancer | Arsenic Trioxid... Stereotactic ra... | 18 Years - | Stanford University | |
| Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine | NCT00053222 | Pancreatic Canc... | arsenic trioxid... | 18 Years - | University of Chicago | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | NCT00008697 | Leukemia | arsenic trioxid... | - | Washington University School of Medicine | |
| Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer | NCT06088030 | Pediatric Cance... Li-Fraumeni Syn... p53 Mutations | Arsenic trioxid... | - 18 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | NCT03381781 | Acute Myeloid L... P53 Mutation | Decitabine Arsenic Trioxid... Cytarabine | 18 Years - 75 Years | Ruijin Hospital | |
| Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | NCT00093483 | Leukemia | filgrastim arsenic trioxid... cytarabine idarubicin | 18 Years - 59 Years | Roswell Park Cancer Institute | |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | NCT00661544 | Multiple Myelom... Stem Cell Trans... | Arsenic Trioxid... Melphalan Ascorbic Acid | - 70 Years | M.D. Anderson Cancer Center | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | NCT00075413 | Breast Cancer | arsenic trioxid... | 18 Years - 120 Years | The University of Texas Medical Branch, Galveston | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | NCT00005595 | Lymphoma | arsenic trioxid... | 16 Years - | Northwestern University | |
| Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | NCT00528450 | Leukemia | arsenic trioxid... idarubicin tretinoin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) | NCT03377725 | Myelodysplastic... P53 Mutation | Decitabine Arsenic Trioxid... | 18 Years - 75 Years | Ruijin Hospital | |
| Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00075426 | Lung Cancer | arsenic trioxid... | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00061958 | Adenocarcinoma ... Stage III Esoph... Stage IV Esopha... | arsenic trioxid... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | NCT00671697 | Myelodysplastic... | Arsenic Trioxid... Decitabine | 18 Years - | Washington University School of Medicine | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | NCT00005786 | Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac... | arsenic trioxid... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide in Treating Men With Germ Cell Cancer | NCT00036842 | Extragonadal Ge... Testicular Germ... | arsenic trioxid... | 16 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | NCT00112879 | Stage I Multipl... Stage II Multip... Stage III Multi... Refractory Plas... | arsenic trioxid... ascorbic acid dexamethasone thalidomide anti-cytokine t... antiangiogenesi... biological ther... chemotherapy drug resistance... growth factor a... non-specific im... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | NCT00193544 | Multiple Myelom... | Arsenic Trioxid... Thalidomide | 18 Years - | SCRI Development Innovations, LLC | |
| Acute Promyelocytic Leukemia 2006 (APL) | NCT00378365 | Leukemia, Promy... | Arsenic trioxid... ATRA | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00118196 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - 120 Years | Medical University of South Carolina | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma | NCT01861912 | Carcinoma, Hepa... | Arsenic trioxid... Arsenic trioxid... lipiodol NaCl solution | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00075426 | Lung Cancer | arsenic trioxid... | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector | NCT01428128 | Cancer Other Th... | Arsenic Trioxid... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | NCT00005595 | Lymphoma | arsenic trioxid... | 16 Years - | Northwestern University | |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | NCT01409161 | Acute Promyeloc... | Arsenic Trioxid... Gemtuzumab Ozog... Laboratory Biom... Tretinoin | 10 Years - | M.D. Anderson Cancer Center | |
| Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | NCT00985530 | Acute Promyeloc... | Tamibarotene Arsenic trioxid... | 18 Years - | Northwestern University | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy | NCT00004149 | Prostate Cancer | arsenic trioxid... | - 120 Years | Albert Einstein College of Medicine | |
| Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma | NCT00185861 | Brain Cancer | Arsenic Trioxid... Stereotactic ra... | 18 Years - | Stanford University | |
| Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | NCT00513305 | Acute Myeloid L... | Arsenic trioxid... Low-dose cytara... | 60 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol | NCT05682131 | Arsenic Trioxid... Childhood ALL | Realgar Indigo ... Conventional ch... | 1 Year - 14 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT00193518 | Chronic Lymphoc... Small Lymphocyt... | Arsenic Trioxid... | 18 Years - | SCRI Development Innovations, LLC | |
| Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma | NCT00006021 | Multiple Myelom... | ascorbic acid arsenic trioxid... | 18 Years - 120 Years | University of Miami | |
| Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00227682 | Multiple Myelom... | ascorbic acid arsenic trioxid... dexamethasone thalidomide | 18 Years - | OHSU Knight Cancer Institute | |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin | NCT00413166 | Acute Promyeloc... | All-Trans Retin... Arsenic Trioxid... Idarubicin Gemtuzumab Ozog... | - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | NCT00276601 | Leukemia | arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin | 5 Years - 74 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | NCT02066870 | Non-small Cell ... | Icotinib Arsenic trioxid... | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | NCT00276601 | Leukemia | arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin | 5 Years - 74 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | NCT00003934 | Adult Acute Mye... Adult Acute Pro... Childhood Acute... Untreated Adult... Untreated Child... | tretinoin daunorubicin hy... cytarabine mercaptopurine methotrexate arsenic trioxid... | - | National Cancer Institute (NCI) | |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
| A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | NCT00582400 | Carcinoma, Hepa... | arsenic trioxid... | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | NCT04518501 | Efficacy and Sa... | Arsenic trioxid... | 18 Years - 70 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL | NCT02757040 | Leukemia, Lymph... | Ibrutinib combi... ibrutinib | 18 Years - 90 Years | Peking University People's Hospital | |
| Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | NCT00193544 | Multiple Myelom... | Arsenic Trioxid... Thalidomide | 18 Years - | SCRI Development Innovations, LLC | |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | NCT01404949 | Acute Promyeloc... | Tretinoin and A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) | NCT03377725 | Myelodysplastic... P53 Mutation | Decitabine Arsenic Trioxid... | 18 Years - 75 Years | Ruijin Hospital | |
| Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment | NCT00449137 | Colorectal Canc... | Arsenic trioxid... Fluorouracil Leucovorin calc... Plasma levels o... Peripheral Bloo... Tumor Biopsy (F... | 18 Years - 120 Years | University of Miami | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | NCT00258245 | Multiple Myelom... | ascorbic acid arsenic trioxid... bortezomib dexamethasone thalidomide Aspirin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | NCT04518501 | Efficacy and Sa... | Arsenic trioxid... | 18 Years - 70 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL | NCT02757040 | Leukemia, Lymph... | Ibrutinib combi... ibrutinib | 18 Years - 90 Years | Peking University People's Hospital | |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | NCT02339740 | Acute Promyeloc... | Arsenic Trioxid... Cytarabine Dexamethasone Idarubicin Laboratory Biom... Mitoxantrone Hy... Quality-of-Life... Questionnaire A... Tretinoin | 12 Months - 21 Years | Children's Oncology Group | |
| Arsenic Trioxide in Treating Men With Germ Cell Cancer | NCT00036842 | Extragonadal Ge... Testicular Germ... | arsenic trioxid... | 16 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | NCT00005786 | Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac... | arsenic trioxid... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment | NCT00449137 | Colorectal Canc... | Arsenic trioxid... Fluorouracil Leucovorin calc... Plasma levels o... Peripheral Bloo... Tumor Biopsy (F... | 18 Years - 120 Years | University of Miami | |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | NCT03031249 | AML | Cytarabine all-trans retin... Arsenic Trioxid... | 14 Years - 55 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00061958 | Adenocarcinoma ... Stage III Esoph... Stage IV Esopha... | arsenic trioxid... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine | NCT00053222 | Pancreatic Canc... | arsenic trioxid... | 18 Years - | University of Chicago | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | NCT04996030 | Acute Promyeloc... | SY-2101 Arsenic Trioxid... | 18 Years - | Syros Pharmaceuticals | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01835288 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... | arsenic trioxid... laboratory biom... | 18 Years - | Stanford University | |
| Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery | NCT00275067 | Brain and Centr... | arsenic trioxid... temozolomide radiation thera... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
